Introduction
============

Asthma is a respiratory disease characterized by airway inflammation, airway hyper-responsiveness, and resultant reversible airway obstruction. Approximately 12% of children are afflicted with the disease, and it is the most common cause of childhood hospitalizations.[@b1-jaa-6-023] Asthma therapy revolves around managing respiratory symptoms, airway inflammation, and airway hyper-responsiveness.[@b1-jaa-6-023] Commonly used agents include bronchodilators and inhaled corticosteroids.[@b1-jaa-6-023] Patients with more severe asthma require daily oral steroid therapy and occasionally immunosuppressive agents.

When managing chronic asthma in children, any side effects of the treatment modality become important. Recently, long-acting beta-agonists have received a black-box warning for monotherapy.[@b2-jaa-6-023] Furthermore, corticosteroids are notorious for a wide range of detrimental effects, such as growth retardation, decreased bone mineral density, skin thinning, cataracts, glucose intolerance, hypertension, central obesity, and suppression of the hypothalamic-pituitary-adrenal axis.[@b2-jaa-6-023],[@b3-jaa-6-023] The 2008 Childhood Asthma Management Program study of long-term oral corticosteroid use in children with asthma found a dose-dependent increase in risk of osteopenia and a decrease in bone mineral accrual.[@b4-jaa-6-023] Significant improvement in chronic treatment of asthma in children is necessary to address the morbidity and mortality associated with current approaches.

Antibiotics, especially macrolides, have been extensively investigated as a potential treatment in asthma, chronic obstructive pulmonary disease, and cystic fibrosis.[@b5-jaa-6-023],[@b6-jaa-6-023] Although many clinicians prescribe antibiotics in the setting of chronic asthma and its exacerbations, current national guidelines discourage such use.[@b7-jaa-6-023],[@b8-jaa-6-023] Nevertheless, due to their anti-inflammatory and antibacterial effects, macrolides show great potential as an adjunct treatment for asthma.[@b9-jaa-6-023] Since the late 1950s, macrolide therapy has been recognized to improve outcomes in children and adults with asthma.[@b10-jaa-6-023]--[@b16-jaa-6-023] In 1970, Itkin and Menzel[@b17-jaa-6-023] reported a steroid-sparing effect of macrolides. In agreement with Itkin and Menzel, in a randomized controlled trial designed to investigate the effects of macrolide therapy on childhood asthma, Kamada et al[@b14-jaa-6-023] showed a statistically significant steroid-sparing effect and an improvement in forced expiratory volume in one second (FEV~1~). In contrast, a Cochrane meta-analysis of macrolide use for chronic asthma in children and adults showed insufficient evidence to support or refute use of macrolides.[@b18-jaa-6-023] The present systematic review and meta-analysis was undertaken to determine the effect of macrolide therapy on management of asthma in children.

Materials and methods
=====================

We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria when performing this study. The MEDLINE and EBM (Evidence-Based Medicine) Reviews/Cochrane Central Register of Controlled Trials databases were searched using both the Ovid and PubMed search engines, covering the period from 1950 to 2009. Search terms included "macrolides", "asthma", and "children", with a focus on the subtopics "treatment" and "therapy". A review of the bibliographies of selected references was also performed.

Study selection and data extraction
-----------------------------------

Inclusion criteria were a clinical diagnosis of asthma, age 2--18 years, a macrolide antibiotic used as an adjunctive controller, oral corticosteroid use with dosage determined before and after initiation of macrolide therapy, and FEV~1~ as percent predicted measured before and after initiation of macrolide therapy. Studies were excluded if presented as a review article or meta-analysis or if patients with chronic respiratory conditions other than asthma, such as cystic fibrosis, were included. The studies recovered from the database searches were screened by title, abstract, and article type. The methods sections from those studies that survived the initial cull were blindly reviewed for compliance with our inclusion criteria by MD and RL.

Statistical analysis
--------------------

Differences in mean FEV~1~ and daily oral dosage of corticosteroids before and after therapy were computed for each study and for all studies combined. Heterogeneity among studies was determined by Cochrane's Q statistic and by calculating the resulting *P* value. A *P* \< 0.05 was suggestive of significant heterogeneity. I^2^ was calculated to determine the extent of heterogeneity across studies. In cases where heterogeneity was significant, the studies were combined using the random-effects model. The effect of duration of macrolide therapy on daily oral corticosteroid dosage was determined by meta-regression; a *P* value \< 0.05 for the slope of the regression line was considered to be statistically significant. All analyses were performed with meta-analysis software (Comprehensive Meta-Analysis version 2.0, Biostat Inc, Englewood, NJ, <http://www.meta-analysis.com>).

Results
=======

Literature flow
---------------

The Ovid, MEDLINE, and PubMed searches yielded 116 references for review. From the 116 titles and abstracts, 22 references were excluded. The full text of 94 references was then reviewed and another 79 references were excluded, resulting in a total of 15 studies that were then reviewed by blinded team members (MD and RL). Of the 15 references, six[@b11-jaa-6-023]--[@b16-jaa-6-023] were included in the final report ([Figure 1](#f1-jaa-6-023){ref-type="fig"}, [Table 1](#t1-jaa-6-023){ref-type="table"}). Because only two[@b11-jaa-6-023],[@b14-jaa-6-023] of the six included studies used a placebo group, the present study considered the pre and post-treatment groups only to maintain homogeneity.

The total pediatric sample size of the combined studies was 69. Five prospective studies[@b11-jaa-6-023]--[@b15-jaa-6-023] were identified and included in the analysis of macrolide therapy and FEV~1~ change ([Table 2](#t2-jaa-6-023){ref-type="table"}, [Figure 2](#f2-jaa-6-023){ref-type="fig"}). Four studies[@b13-jaa-6-023]--[@b16-jaa-6-023] were included in the analysis of macrolide therapy and oral corticosteroid dose change ([Table 3](#t3-jaa-6-023){ref-type="table"}, [Figure 3](#f3-jaa-6-023){ref-type="fig"}), three of which were included in the subgroup meta-regression analysis.[@b13-jaa-6-023]--[@b15-jaa-6-023]

Of note, four of six[@b11-jaa-6-023]--[@b14-jaa-6-023] studies specifically excluded patients with evidence of upper respiratory illness or viral infection. Piacentini et al reported that none of the patients in their study had clinical signs or symptoms or airway infections in the months before or during the study.[@b11-jaa-6-023] Shimizu et al required that their subjects were free from upper respiratory tract infections for 4 weeks prior to study entry.[@b12-jaa-6-023] Zieger et al noted that no patients had evidence of infection at the start of the study.[@b13-jaa-6-023] Kamada et al excluded all patients who had evidence of respiratory infection within 4 weeks of enrollment.[@b14-jaa-6-023] Eitches et al[@b15-jaa-6-023] and Flotte et al[@b16-jaa-6-023] did not specify viral illness as an exclusion criterion.

FEV~1~ change
-------------

[Table 2](#t2-jaa-6-023){ref-type="table"} presents the five studies included in the analysis of the effects of macrolide on FEV~1~ in children with asthma. Due to significant heterogeneity across studies (I^2^ = 89.80, Q = 39.23, *P* = 0.002), the random-effects model was used. As seen in [Figure 2](#f2-jaa-6-023){ref-type="fig"}, macrolide therapy had no impact overall on changes in FEV~1~. When subsets of studies were investigated, macrolide therapy failed to impact FEV~1~ in patients who were not oral corticosteroid-dependent (standard difference in mean = 0.15% predicted; 95% CI −0.47, 0.77, *P* = 0.63), but had a significant impact on oral corticosteroid-dependent patients (standard difference in mean = 3.89% predicted; 95% CI −0.01, 7.79, *P* = 0.05).

Change in oral corticosteroid dose
----------------------------------

[Table 3](#t3-jaa-6-023){ref-type="table"} and [Figure 3](#f3-jaa-6-023){ref-type="fig"} present the four studies included in the analysis of the effects of macrolide on oral corticosteroid dosing in children with asthma. The random-effects model was used due to significant heterogeneity across studies (I^2^ = 82.49, Q = 17.14, *P* \< 0.05). Addition of macrolide therapy in children with oral corticosteroid-dependent asthma resulted in a statistically significant decrease in daily corticosteroid dosage (−3.45 mg/day; 95% CI −5.79, −1.09, *P* = 0.004). The effect of duration of macrolide therapy on daily oral corticosteroid dosage was determined by meta-regression. As the duration of macrolide therapy increased, the daily oral corticosteroid dosage was reduced by 0.17 mg per week (95% CI = 0.021 −0.33 mg of Methylprednisolone per week of macrolide therapy, *P* = 0.025).

Discussion
==========

The present study found that while adjunctive macrolide therapy did not affect FEV~1~ in children without oral corticosteroid-dependent asthma, FEV~1~ improved in children with oral corticosteroid-dependent asthma. Moreover, among children requiring daily oral corticosteroids for control of asthma, addition of a macrolide agent decreased daily oral corticosteroid dosage requirements, and the degree of this reduction was directly proportional to duration of macrolide therapy.

While the utility of macrolide therapy in asthma has been well studied in the general population, it has been poorly studied in childhood asthma. Richeldi et al[@b18-jaa-6-023] reviewed randomized controlled trials of macrolide administration in patients with asthma, and identified a sample size of 398 adults from six studies, and 18 children from one study. This meta-analysis found insufficient evidence to recommend macrolide therapy in patients with chronic asthma. In particular, the authors failed to find that macrolide therapy had a significant impact on daily oral corticosteroid dosage. This last conclusion was based on two studies. Nelson et al[@b19-jaa-6-023] studied 75 adults and did not find a difference in daily oral corticosteroid dosage between their treatment and placebo groups. Kamada et al[@b14-jaa-6-023] studied 11 children, and found a statistically significant reduction in daily oral corticosteroid dosage for children receiving macrolide therapy when compared with a placebo group. The present study, which found an effect of macrolide therapy on daily oral corticosteroid dosage, included parallel and crossover clinical trials involving only children. These observations suggest that macrolide therapy may have a steroid-sparing effect in children but not in adults. Further studies are needed to resolve this issue.

Potential mechanisms of macrolide effects are likely related to modulation of inflammatory cytokines, such as interleukin (IL)-5, IL-8, and vascular endothelial growth factor (VEGF). In a prospective cohort study from 2010, Korematsu et al[@b20-jaa-6-023] showed a correlation between children with severe asthma and high levels of IL-8 and VEGF. Furthermore, that study showed that low-dose erythromycin significantly improved clinical symptoms and decreased levels of both IL8 and VEGF in children with severe asthma, but not in children with mild to moderate asthma.[@b20-jaa-6-023] In a cross-sectional controlled study performed in 2011, Lin et al[@b21-jaa-6-023] showed that children with asthma produced significantly higher levels of IL-5 compared with children without asthma, and addition of azithromycin significantly decreased IL-5 levels in a dose-dependent fashion. In the present study, the most severely affected children, ie, those who were dependent on oral corticosteroids, saw the most benefit from macrolide therapy, a result that is likely related to the pathophysiology observed in the Korematsu et al[@b20-jaa-6-023] study. It is unclear why children but not adults (as determined by a Cochrane review[@b18-jaa-6-023]) show significant steroid-sparing effects from adjunctive macrolide therapy. The common saying may be appropriate here, ie, that "children are not simply young adults".

The present study has several limitations. First, troleandomycin and methylprednisolone were used in all studies where a steroid-sparing effect was observed. Prior studies have suggested a pharmacokinetic interaction between these two agents that directly increases steroid concentrations.[@b13-jaa-6-023],[@b22-jaa-6-023] It is not known whether this same effect exists between other members of the macrolide and corticosteroid classes. Another significant limitation is sample size: our aggregate data analyzed a total of 69 patients from six studies, and four of these (n = 28) were analyzed for steroid-sparing effect. Nevertheless, to the authors' knowledge, this is the largest sample size to date to have evaluated the effect of macrolides in children with corticosteroid-dependent asthma. Further, the studies were performed many years earlier, in some cases 30 years ago, when definitions and standard of care protocols were different from those used today. Furthermore, although the improvement in FEV~1~ was statistically significant, it may not necessarily be clinically significant, and future studies should include outcomes, such as responses to an asthma symptom questionnaire and numbers of acute care visits.

In summary, this study demonstrates that macrolides have a steroid-sparing effect in children with steroid-dependent asthma. In addition, we found a direct association between duration of macrolide therapy and magnitude of change in oral corticosteroid dosage before and after therapy. The present study supports the need for a large, randomized, placebo-controlled, crossover trial of a modern macrolide in children with steroid-dependent asthma.
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![Flow chart of publications included in systematic review.\
**Abbreviations:** FEV~1~, forced expiratory volume in one second; OCS, oral corticosteroids.](jaa-6-023f1){#f1-jaa-6-023}

![Random effects model analysis of adjunctive macrolide use and FEV~1~ change in children with asthma.\
**Notes:** Grouping by oral corticosteroid use. I^2^ = 89.80, Q = 39.23, *P* \< 0.002.\
**Abbreviations:** CI, confidence interval; FEV~1~, forced expiratory volume in one second.](jaa-6-023f2){#f2-jaa-6-023}

![Random effects model analysis of adjunctive macrolide use and oral steroid dose change in children with asthma.\
**Notes:** I^2^ = 82.49, Q = 17.14, *P* \< 0.05.](jaa-6-023f3){#f3-jaa-6-023}

###### 

Characteristics of studies included in meta-analysis of macrolide use in childhood asthma

  Study                                                                         n    Age range, years   Outcome: FEV~1~ change or OCS dose change   Macrolide       Macrolide dosing                                   OCS    Duration of macrolide therapy, weeks
  ----------------------------------------------------------------------------- ---- ------------------ ------------------------------------------- --------------- -------------------------------------------------- ------ --------------------------------------
  Piacentini et al[@b11-jaa-6-023] (Italy)                                      16   13.4 (mean)        FEV~1~ only                                 Azithromycin    10 mg/kg/day, 3 days/week                          None   8
  Shimizu et al[@b12-jaa-6-023] (Japan)                                         12   11--15             FEV~1~ only                                 Roxithromycin   150 mg/day                                         None   8
  Zeiger et al[@b13-jaa-6-023] (US)                                             3    13--16             FEV~1~ and OCS                              TAO             1 g/day, tapered to 250 mg/day                     MPn    6
  Kamada et al[@b14-jaa-6-023],[€](#tfn2-jaa-6-023){ref-type="table-fn"} (US)   18   6--17              FEV~1~ and OCS                              TAO             250 mg/day tapered to 250 mg once daily            MPn    12
  Eitches et al[@b15-jaa-6-023] (US)                                            11   7--13              FEV~1~ and OCS                              TAO             1 g/day, tapered to 250 mg/day                     MPn    52
  Flotte et al[@b16-jaa-6-023] (US)                                             9    2--14              OCS only                                    TAO             250 mg twice daily, tapered to 250 mg once daily   MPn    16--136

**Note:**

The only study included in the Cochrane meta-analysis.

**Abbreviations:** MPn, methylprednisolone; TAO, troleandomycin; FEV~1~, forced expiratory volume in one second; OCS, oral corticosteroids.

###### 

Changes in FEV~1~ with addition of macrolide

  Study                              OCS use   Macrolide       n                                             Duration of macrolide treatment   Pretreatment FEV~1~ ± SEM   Post treatment FEV~1~   *P*
  ---------------------------------- --------- --------------- --------------------------------------------- --------------------------------- --------------------------- ----------------------- ------
  Piacentini et al[@b11-jaa-6-023]   No        Azithromycin    8[\#](#tfn5-jaa-6-023){ref-type="table-fn"}   8 weeks                           73.5 ± 12.9                 74.62 ± 9.76            0.84
  Shimizu et al[@b12-jaa-6-023]      No        Roxithromycin   12                                            8 weeks                           81.5 ± 2.2                  82.0 ± 3.0              0.64
  Zeiger et al[@b13-jaa-6-023]       Yes       TAO             3                                             6 weeks                           67.3 ± 12.4                 100 ± 6.0               0.01
  Kamada et al[@b14-jaa-6-023]       Yes       TAO             6                                             12 weeks                          80.4 ± 6.5                  73.6 ± 6.3              0.00
  Eitches et al[@b15-jaa-6-023]      Yes       TAO             11                                            52 weeks                          54 ± 4.8                    97 ± 6.5                0.08

**Notes:** Excluded from this analysis because post treatment FEV~1~ values were not recorded;

only patients from the treatment group were used in our study to maintain homogeneity as described in the results section.

**Abbreviations:** TAO, troleandomycin; FEV~1~, forced expiratory volume in one second; OCS, oral corticosteroids; SEM, standard error of the mean.

###### 

Changes in OCS dose with addition of macrolide

  Study                           Macrolide   OCS   n                                              Duration of macrolide treatment (weeks)            Pretreatment OCS dose ± SEM (mg/day)   Post treatment OCS dose ± SEM (mg/day)   *P*
  ------------------------------- ----------- ----- ---------------------------------------------- -------------------------------------------------- -------------------------------------- ---------------------------------------- -------
  Zeiger et al[@b13-jaa-6-023]    TAO         MPn   3                                              6                                                  19.3 ± 6.8                             14.7 ± 4.7                               0.002
  Kamada et al[@b14-jaa-6-023]    TAO         MPn   6[\#](#tfn10-jaa-6-023){ref-type="table-fn"}   12                                                 34.2 ± 9.6                             4.9 ± 1.0                                0.00
  Eitches et al[@b15-jaa-6-023]   TAO         MPn   10[£](#tfn8-jaa-6-023){ref-type="table-fn"}    52                                                 19.8 ± 3.1                             3.2 ± 0.4                                0.00
  Flotte et al[@b16-jaa-6-023]    TAO         MPn   9                                              16--136[Ω](#tfn9-jaa-6-023){ref-type="table-fn"}   15.3 ± 3.04                            1.4 ± 0.26                               0.245

**Notes:** Piacentini et al and Shimizu et al are excluded because their patients were not OCS-dependent.

Although there were 11 patients in the study, one patient's baseline methylprednisolone dose was described as "variable" and not included in this analysis;

duration of therapy was not specified per patient;

only the patients from the TAO-MPn group were used in our study to maintain homogeneity as described in the results section.[@b13-jaa-6-023]--[@b15-jaa-6-023] The studies included in the meta-regression analysis. Flotte et al was excluded because duration was not discretely defined for each patient.

**Abbreviations:** TAO, troleandomycin; OCS, oral corticosteroids; MPn, methylprednisolone; SEM, standard error of the mean.

[^1]: Raemma Luck is now deceased
